RLAY · Relay Therapeutics, Inc.

Current Thesis

Relay Therapeutics' zovegalisib thesis rests on Phase 3 enrollment progress restoring clinical support for the shares; a quantified update by year-end 2026 and a weekly close above the $20.75 reference high would establish the recovery case, while a weekly close below $17.50 would invalidate it. Management's August 6 release guides an enrollment update by year-end; the September 18 adjusted close was $18.84, according to the supplied public daily-bar series. August 6 corporate update

The September conference window has elapsed: the company's calendar now lists the September 8 and September 16 appearances as past events and shows no upcoming event. That establishes calendar status, not what management said during those webcasts. The next substantive checkpoint remains company-guided year-end disclosure. Company event calendar, checked September 20

As an inference, the narrative is saturated — the August 7–20 analyst-target cluster is established, and the September 18 close remains below both the August 25 holder-sale price of $19.40 and the $20.75 reference high. This retains the September 6 assessment without assuming that every subsequent session represented distribution. A weekly close above $20.75 accompanied by quantified enrollment progress would overturn that assessment.

Bullish and bearish views on Relay Therapeutics, Inc.

The model's bull view on Relay Therapeutics, Inc. (RLAY), in brief: Cash supports clinical execution. Relay reported $910.9 million in cash, cash equivalents and investments at June 30, 2026, and guided runway into 2029 in its August 6 results. That runway is management's forecast, rather than a guarantee against further issuance. Second-quarter… The bear view: Large-holder supply remains observable. SVF Pauling sold 6,000,000 shares at $19.40 on August 25, 2026, according to the August 28 Form 4 cited in the supplied public record. The September 18 close of $18.84 remains below that transaction price; this comparison does not… Both cases follow in full.

Bull Case

• Cash supports clinical execution. Relay reported $910.9 million in cash, cash equivalents and investments at June 30, 2026, and guided runway into 2029 in its August 6 results. That runway is management's forecast, rather than a guarantee against further issuance. Second-quarter results
• Clinical activity anchors the story. Relay's March 16, 2026 presentation reported median progression-free survival of 11.1 months for zovegalisib plus fulvestrant at the Phase 3 dose. This measures time before disease progression or death; it does not establish comparative efficacy against another trial's population. March 16 clinical release
• Analysts established higher valuation references. The supplied August coverage record places Citizens' August 10 target at $26 and JPMorgan's August 14 target at $31. These are attributed analyst views, not measured clinical outcomes or evidence that either target will be reached.

Bear Case

• Large-holder supply remains observable. SVF Pauling sold 6,000,000 shares at $19.40 on August 25, 2026, according to the August 28 Form 4 cited in the supplied public record. The September 18 close of $18.84 remains below that transaction price; this comparison does not establish the seller's future intentions.
• Issuance capacity is not issuance. The August 6, 2026 prospectus supplement expanded the at-the-market equity program to $462,978,049, according to the supplied filing record. Actual subsequent sales are not established by the authorization, so dilution cannot be quantified from that figure alone.
• September filings need transaction detail. Securities and Exchange Commission filing indexes show September 9, 2026 Form 4 reports for CEO Sanjiv Patel and CFO Thomas Catinazzo, each covering September 8. Those indexes alone do not establish transaction quantities, prices or whether activity was discretionary. Patel filing index, Catinazzo filing index

Setup & Price Structure

The September 18, 2026 adjusted daily close was $18.84, with a three-month price increase of 9.0% and a reported distance of 9.2% below the $20.75 52-week high. The 14-day relative strength index, a momentum measure, was 51.2. These are measurements from the supplied daily-bar series.

The September 4 reference close was $19.04 with a relative strength index of 35.1. The newer momentum reading is higher while the newer closing price is lower; these observations do not establish expanding participation. No moving-average value, volume series or short-interest measurement is supplied, so neither moving-average extension nor squeeze crowding can be measured.

The $19.40 August 25 block price is a public transaction reference, and $20.75 is the September 18 reference high. A weekly close above $20.75 would satisfy the price component of the recovery case. The $17.50 weekly-close threshold defines thesis failure; the available observations do not independently establish it as a newly tested support shelf.

Catalyst Calendar (next 30 days)

For September 20–October 20, 2026, no confirmed company event was identified on Relay's event calendar when checked September 20. The September 8 and September 16 conferences have elapsed and are not upcoming catalysts. Company event calendar

• 2026-12-31 — Guided disclosure deadline. Relay's August 6 update promises a ReDiscover-2 enrollment update by year-end, alongside a frontline trial-design regulatory update and a vascular-anomalies data and regulatory update. December 31 represents the end of that guidance window, not a scheduled presentation. A missing or unquantified enrollment update would fail the execution component of the recovery case. Company milestone guidance

What Would Change Our Mind

Loss of the published price threshold would end the recovery thesis: a weekly close below $17.50 is the gradeable invalidation condition. That price event would invalidate this market thesis even if clinical development continued.

Conversely, quantified ReDiscover-2 enrollment progress by December 31, 2026, together with a weekly close above the September 18 reference high of $20.75, would establish the stated recovery case. Enrollment progress alone would not establish drug efficacy, and a price breakout alone would not satisfy the clinical-execution condition.

Correlation Notes

This is a single-name clinical setup: the supplied September 20, 2026 coverage context assigns no active theme cluster to Relay. No paired sector-return series is provided, so a numerical correlation or a claim that a biotechnology group move explains the shares is unsupported.

The August 6 corporate update places both breast-cancer development and vascular-anomalies development under zovegalisib. The inference is shared molecule risk across those programs; separate indications do not constitute independent clinical assets. A company-disclosed safety signal affecting both programs would confirm that transmission risk. Program update